ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

ClinicalTrials.gov ID: NCT03558503

Public ClinicalTrials.gov record NCT03558503. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 8:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Single-Arm, Multicenter Trial to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk of Recurrence

Study identification

NCT ID
NCT03558503
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
UroGen Pharma Ltd.
Industry
Enrollment
63 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 14, 2018
Primary completion
Jan 2, 2020
Completion
Oct 20, 2020
Last update posted
Sep 15, 2022

2018 – 2020

United States locations

U.S. sites
17
U.S. states
13
U.S. cities
14
Facility City State ZIP Site status
Mayo Clinic Cancer Center Phoenix Arizona 85054
Arkansas Urology Little Rock Arkansas 72211
Loma Linda University Loma Linda California 92350
Providence Medical Institute Santa Monica California 90404
Clinical Research Center of Florida Pompano Beach Florida 33060
John Hopkins University Baltimore Maryland 21218
Adult & Pediatric Urology, PC Omaha Nebraska 68114
Urology Las Vegas Las Vegas Nevada 89144
Manhattan Medical Research New York New York 10016
Weill Cornell Medical College New York New York 10065
Montefiore Medical Center (Albert Einstein) New York New York 10461
Western New York Urology Associates New York New York 14225
The University of North Carolina Chapel Hill North Carolina 27572
Penn State Hershey State College Hershey Pennsylvania 17033
Carolina Urologic Research Center Myrtle Beach South Carolina 29572
Urology Associates, PC Nashville Tennessee 37209
Urology San Antonio Fredericksburg Texas 78233

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03558503, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 15, 2022 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03558503 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →